Semaglutide is the “generic name” for Ozempic, Rybelsus, and Wegovy. Novo Nordisk manufactures all three brand-name medications. Ozempic and Rybelsus are FDA-approved to treat type-2 diabetes, and Wegovy is FDA-approved for long-term weight management. Since the FDA-approved Wegovy in 2021 for adults with overweight and obesity, there has been a lot of online conversation about these three drugs. The demand for Wegovy has been so high that there are shortages. This leads many people to ask questions. Can Ozempic and Rybelsus be used instead of Wegovy? Is there a shortage of these two medications as well? Where can you get semaglutide online?
In This Article
Novo Nordisk has manufactured and sold FDA-approved Ozempic since 2017 and Rebelsus since 2019 to treat type-2 diabetes. Semaglutide has an interesting side effect. It causes weight loss. This side effect was viewed as a positive since overweight and obesity are contributing factors to developing type 2 diabetes.
Researchers at Northwestern University speculated that an increased semaglutide dose might be a ‘game changer’ in helping patients with overweight and obesity lose excess pounds. After several clinical trials, their speculation was proven true. There is a relationship between semaglutide dosage and weight loss. Participants in the clinical trials lost, on average, almost 15% of their body weight, compared to the placebo group participants, who lost a mere 2.4%.
The most common side effects are gastrointestinal. Clinical trial participants reported nausea, vomiting, diarrhea, constipation, gas, stomach pain, and heartburn. There was also an increased incidence of gallbladder disease. These side effects are common with all glucagon-like peptide 1 (GLP-1) agonists.
GLP-1 agonists are in the drug class called incretin mimetics. Incretins are hormones released by the gastrointestinal tract that stimulate the pancreas to produce more insulin and lower blood sugar. Since type 2 diabetes is characterized by elevated blood sugar due to an inability to use insulin effectively, it makes sense to use a GLP-1 agonist to stimulate increased insulin release.
GLP-1s also act on the brain to regulate appetite and reduce hunger, an effect that can cause weight loss. In addition, GLP-1 agonists, such as semaglutide, also bind to receptors on the stomach lining, slowing stomach emptying. This makes you feel full longer, also contributing to weight loss. But it causes the gastrointestinal side-effects associated with GLP-1 agonists.
Ozempic, Rybelsus, and Wegovy are all semaglutide. Novo Nordisk manufactures all three drugs. Here is a handy table comparing the three medications.
|Medical indication||Type 2 diabetes||Type 2 diabetes||Weight Management|
|Dosing||Once daily, 3, 7, or 14 mg||Weekly 0.25, 0.5 or 1mg||Weekly 0.25, 0.5, 1.7 or 2.4 mg|
|Most common side effects||Gastrointestinal||Gastrointestinal||Gastrointestinal|
|Prices on GoodRx||$886 to $928||$886 to $922||$1327 to $1401|
More semaglutide combinations and other weight management drugs are being developed, promising even greater weight loss. A combination of a human amylin analogue and semaglutide resulted in a 15% to 17% weight loss in just 20 weeks, with no evidence that weight loss would slow.
Tirzepatide is a gastric inhibitory peptide/ GLP-1 receptor agonist that resulted in more than 10% weight loss and a decline in HgA1c results by 2.5%. Over half of the participants in the clinical trial achieved normal glucose levels.
Setmelanotide is an Mc4R agonist targeted for people with congenital obesity who carry the MC4R loss of function gene variant. Setmelanitide is FDA-approved for patients age six and older with obesity secondary to POMC, PCSK1, and LEPR deficiency.
Oral superabsorbent hydrogel (Gelesis) is biodegradable and food-quality. As it expands to simulate fullness, people experience less hunger. Clinical trial results show at least 5% weight loss, with one-fourth achieving 10% or more. Brand name, Plenity, comes in a capsule that is released in the stomach. The cellulose released from the capsule absorbs water. Plenity can hold up to 100 times its weight in water. Plenity is indicated for adults with a BMI of 25 to 40, in conjunction with a healthy diet and exercise.
Finally, bimagrumab is a monoclonal antibody against activin type II receptors. In a clinical trial that enrolled people with type 2 diabetes, participants lost 20.5% of their total body fat mass and had a 3.6% increase in lean mass.
In late 2021, Novo Nordisk announced shortages of Wegovy because of a problem with a manufacturing partner. The shortage is likely to last until mid-2022. Novo Nordisk is trying to accommodate the large market for anti-obesity drugs, but the market is unpredictable. For example, they report that 70% of Wegovy prescriptions are for people who have never taken a medication approved for weight management.
Ozempic, Rybelsus, Wegovy, and semaglutide combinations are all prescription medications that can be obtained online after consulting with a medical professional. This online visit ensures that you meet the indications for the prescription medication, do not have any of the contraindications for taking it, and are aware of the known risks and benefits associated with the medication.
If you are interested in losing excess weight, contact the healthcare professionals at Invigor Medical to learn more about your treatment options using semaglutide or another prescription medication for weight management.
While we strive to always provide accurate, current, and safe advice in all of our articles and guides, it’s important to stress that they are no substitute for medical advice from a doctor or healthcare provider. You should always consult a practicing professional who can diagnose your specific case. The content we’ve included in this guide is merely meant to be informational and does not constitute medical advice.